MedTrace Logo

A Phase I Rheumatoid Arthritis Study in Healthy Volunteers

NCT00539760 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-08-15

No results posted yet for this study

Summary

GSK182771 is a domain antibody targeting the interleukin (IL)-1 receptor which is being developed for the treatment of rheumatoid arthritis. This study is being done in healthy volunteers to verify the safety and tolerability of GSK182771

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

GSK1827771

GSK1827771 will be administered using injection via subcutaneous (SC) route.

DRUG

Placebo

Placebo to GSK1827771 for Injection will be administered via SC route

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-05
Primary Completion
2008-04-05
Completion
2008-04-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00539760 on ClinicalTrials.gov